Drug product production, clinical support studies, and phase 1 trial of a new MS drug

A new drug for multiple sclerosis is about to enter its first human trials, with the first volunteer expected to receive a dose by late 2013. This matters because muscle spasticity—a common and debilitating symptom of MS—is currently treated with drugs that often cause severe side effects, limiting how early and aggressively doctors can intervene. The new compound is designed to be a first-in-class treatment that controls spasticity with fewer and less severe side effects. If successful, it could become the standard of care, allowing patients to start treatment earlier, slow the onset of disability, and maintain a normal life for longer. The project is not fundamental science; it is a translational push toward a licensed medicine. Funding from Innovate UK, alongside support from the Wellcome Trust and UCL Business, covers drug product manufacturing, clinical support studies, and the phase 1 trial itself. If the trial demonstrates safety and tolerability, the drug would move toward larger efficacy studies. A successful outcome would change the daily reality for thousands of MS patients by offering a treatment that does not force them to choose between symptom relief and debilitating side effects.